Neurocritical Care

, Volume 27, Issue 1, pp 17–25 | Cite as

Stroke and Intracranial Hemorrhage in HeartMate II and HeartWare Left Ventricular Assist Devices: A Systematic Review

  • Sung M. Cho
  • Nader Moazami
  • Jennifer A. Frontera
Original Article
First Online:

Abstract

Background

Ischemic stroke and intracranial hemorrhage (ICH) following left ventricular assist device (LVAD) placement are major causes of morbidity. The incidence and mortality associated with these events stratified by device type have not been systematically explored.

Methods

A systematic review of PubMed was conducted from January 2007 through June 2016 for all English-language articles involving HeartMate II (HMII) and HeartWare LVAD patients. Ischemic stroke and/or ICH incidence (events per patient-year) and associated mortality rates were abstracted for each device type.

Results

Of 735 articles reviewed, 48 (11,310 patients) met inclusion criteria (33 HMII, six HeartWare, eight both devices, and one unspecified). The median duration of device support was 112 days (total 13,723 patient-years). Overall, ischemic stroke or ICH occurred in 9.8% (1110 persons and 0.08 events per patient year [EPPY]). Ischemic stroke occurred in a median of 6.0% or 0.06 EPPY (range 0–16% or 0–0.21 EPPY) of HMII patients versus 7.5% or 0.09 EPPY (range 4–17.1% or 0.01–0.94 EPPY) of HeartWare patients. ICH occurred in a median of 3.0% or 0.04 EPPY (range 0–13.5% or 0–0.13 EPPY) of HMII and 8.0% or 0.08 EPPY (range 3–23% or 0.01–0.56 EPPY) of HeartWare patients. The median mortality rate for LVAD-associated ischemic stroke was 31% (HMII: 33%, [range 2.4–75%] and HeartWare: 11.5% [range 3.9–40%]), and the median mortality rate following ICH was 71% (HMII: 75%, [range 3.9–100%] and HeartWare: 44%, [range 3.1–88%]).

Conclusions

Ischemic stroke and ICH are common after LVAD placement, but heterogeneous event rates are reported in the literature. Given the high associated mortality, further prospective study is warranted.

Keywords

Left ventricular assisted device (LVAD) HeartWare (HVAD) HeartMate II (HMII) Ischemic stroke ICH 
This is a preview of subscription content, log in to check access.

Notes

Compliance with Ethical Standards

Conflict of interest

None.

Supplementary material

12028_2017_386_MOESM1_ESM.docx (124 kb)
Supplementary material 1 (DOCX 123 kb)

References

  1. 1.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation. 2013;128:1810–52.CrossRefPubMedGoogle Scholar
  2. 2.
    Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, et al. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transpl. 2015;34:1495–504.CrossRefGoogle Scholar
  3. 3.
    Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. PLoS Med. 2009;6:e1000097.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Miller LW, Pagani FD, Russell SD, John R, Boyle AJ, Aaronson KD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885–96.CrossRefPubMedGoogle Scholar
  5. 5.
    Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–51.CrossRefPubMedGoogle Scholar
  6. 6.
    Karimi A, Beaver TM, Hess PJ, Martin TD, Staples ED, Schofield RS, et al. Close antiplatelet therapy monitoring and adjustment based upon thrombelastography may reduce late-onset bleeding in HeartMate II recipients. Interact CardioVasc Thorac Surg. 2014;18:457–65.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Teuteberg JJ, Slaughter MS, Rogers JG, McGee EC, Pagani FD, Gordon R, et al. The HVAD left ventricular assist device: risk factors for neurological events and risk mitigation strategies. JACC Heart Fail. 2015;3:818–28.CrossRefPubMedGoogle Scholar
  8. 8.
    Wilson TJ, Stetler WR, Al-Holou WN, Sullivan SE, Fletcher JJ. Management of intracranial hemorrhage in patients with left ventricular assist devices. J Neurosurg. 2013;118:1063–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Lalonde SD, Alba AC, Rigobon A, Ross HJ, Delgado DH, Billia F, et al. Clinical differences between continuous flow ventricular assist devices: a comparison between HeartMate II and HeartWare HVAD. J Card Surg. 2013;28:604–10.CrossRefPubMedGoogle Scholar
  10. 10.
    Willey JZ, Gavalas MV, Trinh PN, Yuzefpolskaya M, Reshad Garan A, Levin AP, et al. Outcomes after stroke complicating left ventricular assist device. J Heart Lung Transpl. 2016;35:1003–9.CrossRefGoogle Scholar
  11. 11.
    McIlvennan CK, Magid KH, Ambardekar AV, Thompson JS, Matlock DD, Allen LA. Clinical outcomes after continuous-flow left ventricular assist device: a systematic review. Circ Heart Fail. 2014;7:1003–13.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Stulak JM, Davis ME, Haglund N, Dunlay S, Cowger J, Shah P, et al. Adverse events in contemporary continuous-flow left ventricular assist devices: a multi-institutional comparison shows significant differences. J Thorac Cardiovasc Surg. 2016;151:177–89.CrossRefPubMedGoogle Scholar
  13. 13.
    Coffin ST, Haglund NA, Davis ME, Xu M, Dunlay SM, Cowger JA, et al. Adverse neurologic events in patients bridged with long-term mechanical circulatory support: a device-specific comparative analysis. J Heart Lung Transpl. 2015;34:1578–85.CrossRefGoogle Scholar
  14. 14.
    Morris AA, Pekarek A, Wittersheim K, Cole RT, Gupta D, Nguyen D, et al. Gender differences in the risk of stroke during support with continuous-flow left ventricular assist device. J Heart Lung Transpl. 2015;34:1570–7.CrossRefGoogle Scholar
  15. 15.
    Pagani FDJ, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ. HeartWare HVAD for the treatment of patients with advanced heart failure ineligible for cardiac transplantation: results of the endurance destination therapy trial. J Heart Lung Transpl. 2015;34(4):S9.CrossRefGoogle Scholar
  16. 16.
    Boyle AJ, Russell SD, Teuteberg JJ, Slaughter MS, Moazami N, Pagani FD, et al. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transpl. 2009;28:881–7.CrossRefGoogle Scholar
  17. 17.
    Menon AK, Götzenich A, Sassmannshausen H, Haushofer M, Autschbach R, Spillner JW. Low stroke rate and few thrombo-embolic events after HeartMate II implantation under mild anticoagulation. Eur J Cardiothorac Surg. 2012;42:319–23 (discussion 323).CrossRefPubMedGoogle Scholar
  18. 18.
    Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med. 2005;143:241–50.CrossRefPubMedGoogle Scholar
  19. 19.
    Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969–74.CrossRefPubMedGoogle Scholar
  20. 20.
    van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE. Group AitSPEiCT-A-R. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 2002;360:109–13.CrossRefPubMedGoogle Scholar
  21. 21.
    Puskas J, Gerdisch M, Nichols D, Quinn R, Anderson C, Rhenman B, et al. Reduced anticoagulation after mechanical aortic valve replacement: Interim results from the prospective randomized on-x valve anticoagulation clinical trial randomized food and drug administration investigational device exemption trial. J Thorac Cardiovasc Surg. 2014;147:1202–10 (discussion 1210-1201).CrossRefPubMedGoogle Scholar
  22. 22.
    Bhimaraj A, Uribe C, Suarez EE. Physiological impact of continuous flow on end-organ function: clinical implications in the current era of left ventricular assist devices. Methodist DeBakey Cardiovasc J. 2015;11:12–7.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Aggarwal A, Gupta A, Kumar S, Baumblatt JA, Pauwaa S, Gallagher C, et al. Are blood stream infections associated with an increased risk of hemorrhagic stroke in patients with a left ventricular assist device? ASAIO J. 2012;58:509–13.CrossRefPubMedGoogle Scholar
  24. 24.
    Bogaev RC, Pamboukian SV, Moore SA, Chen L, John R, Boyle AJ, et al. Comparison of outcomes in women versus men using a continuous-flow left ventricular assist device as a bridge to transplantation. J Heart Lung Transpl. 2011;30:515–22.CrossRefGoogle Scholar
  25. 25.
    Boyle AJ, Jorde UP, Sun B, Park SJ, Milano CA, Frazier OH, et al. Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients. J Am Coll Cardiol. 2014;63:880–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Cowger JA, Romano MA, Shah P, Shah N, Mehta V, Haft JW, et al. Hemolysis: a harbinger of adverse outcome after left ventricular assist device implant. J Heart Lung Transpl. 2014;33:35–43.CrossRefGoogle Scholar
  27. 27.
    Daneshmand MA, Krishnamoorthy A, Samsky MD, Felker GM, Pura JA, Lokhnygina Y, et al. Comparison of 2-year outcomes of extended criteria cardiac transplantation versus destination left ventricular assist device therapy using continuous flow. Am J Cardiol. 2015;116:573–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Frazier OH, Gemmato C, Myers TJ, Gregoric ID, Radovancevic B, Loyalka P, et al. Initial clinical experience with the HeartMate II axial-flow left ventricular assist device. Tex Heart Inst J. 2007;34:275–81.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Granfeldt H, Peterzén B, Hübbert L, Jansson K, Ahn H. A single center experience with the HeartMate II left ventricular assist device (lvad). Scand Cardiovasc J. 2009;43:360–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Gregoric ID, Radovancevic R, Patel M, Fenik Y, Cohn WE, Frazier OH. Use of sealed grafts in the HeartMate II left ventricular assist device inflow and outflow conduits. ASAIO J. 2014;60:300–3.CrossRefPubMedGoogle Scholar
  31. 31.
    Harvey L, Holley C, Roy SS, Eckman P, Cogswell R, Liao K, et al. Stroke after left ventricular assist device implantation: outcomes in the continuous-flow era. Ann Thorac Surg. 2015;100:535–41.CrossRefPubMedGoogle Scholar
  32. 32.
    Kato TS, Schulze PC, Yang J, Chan E, Shahzad K, Takayama H, et al. Pre-operative and post-operative risk factors associated with neurologic complications in patients with advanced heart failure supported by a left ventricular assist device. J Heart Lung Transpl. 2012;31:1–8.CrossRefGoogle Scholar
  33. 33.
    Katz MR, Dickinson MG, Raval NY, Slater JP, Dean DA, Zeevi GR, et al. Outcomes of patients implanted with a left ventricular assist device at nontransplant mechanical circulatory support centers. Am J Cardiol. 2015;115:1254–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Klodell CT, Massey HT, Adamson RM, Dean DA, Horstmanshof DA, Ransom JM, et al. Factors related to pump thrombosis with the HeartMate II left ventricular assist device. J Card Surg. 2015;30:775–80.CrossRefPubMedGoogle Scholar
  35. 35.
    Lahpor J, Khaghani A, Hetzer R, Pavie A, Friedrich I, Sander K, et al. European results with a continuous-flow ventricular assist device for advanced heart-failure patients. Eur J Cardiothorac Surg. 2010;37:357–61.PubMedGoogle Scholar
  36. 36.
    Litzler PY, Smail H, Barbay V, Nafeh-Bizet C, Bouchart F, Baste JM, et al. Is anti-platelet therapy needed in continuous flow left ventricular assist device patients? A single-centre experience. Eur J Cardiothorac Surg. 2014;45:55–9 (discussion 59-60).CrossRefPubMedGoogle Scholar
  37. 37.
    Morgan JA, Brewer RJ, Nemeh HW, Gerlach B, Lanfear DE, Williams CT, et al. Stroke while on long-term left ventricular assist device support: incidence, outcome, and predictors. ASAIO J. 2014;60:284–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Pagani FD, Miller LW, Russell SD, Aaronson KD, John R, Boyle AJ, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol. 2009;54:312–21.CrossRefPubMedGoogle Scholar
  39. 39.
    Park SJ, Milano CA, Tatooles AJ, Rogers JG, Adamson RM, Steidley DE, et al. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail. 2012;5:241–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Saeed O, Shah A, Kargoli F, Madan S, Levin AP, Patel SR, et al. Antiplatelet therapy and adverse hematologic events during heart mate ii support. Circ Heart Fail. 2016;9:e002296.CrossRefPubMedGoogle Scholar
  41. 41.
    Salerno CT, Sundareswaran KS, Schleeter TP, Moanie SL, Farrar DJ, Walsh MN. Early elevations in pump power with the HeartMate II left ventricular assist device do not predict late adverse events. J Heart Lung Transpl. 2014;33:809–15.CrossRefGoogle Scholar
  42. 42.
    Slaughter MS, Naka Y, John R, Boyle A, Conte JV, Russell SD, et al. Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. J Heart Lung Transpl. 2010;29:616–24.CrossRefGoogle Scholar
  43. 43.
    Strüber M, Sander K, Lahpor J, Ahn H, Litzler PY, Drakos SG, et al. HeartMate II left ventricular assist device; early European experience. Eur J Cardiothorac Surg. 2008;34:289–94.CrossRefPubMedGoogle Scholar
  44. 44.
    van den Bergh WM, Lansink-Hartgring AO, van Duijn AL, Engström AE, Lahpor JR, Slooter AJ. Thromboembolic stroke in patients with a HeartMate II left ventricular assist device—the role of anticoagulation. J Cardiothorac Surg. 2015;10:128.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Wever-Pinzon O, Selzman CH, Drakos SG, Saidi A, Stoddard GJ, Gilbert EM, et al. Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail. 2013;6:517–26.CrossRefPubMedGoogle Scholar
  46. 46.
    Aaronson KD, Slaughter MS, Miller LW, McGee EC, Cotts WG, Acker MA, et al. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation. 2012;125:3191–200.CrossRefPubMedGoogle Scholar
  47. 47.
    Bashir J, Legare JF, Freed DH, Cheung A, Rao V, Toma M. Multicentre canadian experience with the HeartWare ventricular assist device: concerns about adverse neurological outcomes. Can J Cardiol. 2014;30:1662–7.CrossRefPubMedGoogle Scholar
  48. 48.
    Popov AF, Hosseini MT, Zych B, Mohite P, Hards R, Krueger H, et al. Clinical experience with HeartWare left ventricular assist device in patients with end-stage heart failure. Ann Thorac Surg. 2012;93:810–5.CrossRefPubMedGoogle Scholar
  49. 49.
    Slaughter MS, Pagani FD, McGee EC, Birks EJ, Cotts WG, Gregoric I, et al. HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial. J Heart Lung Transpl. 2013;32:675–83.CrossRefGoogle Scholar
  50. 50.
    Strueber M, O’Driscoll G, Jansz P, Khaghani A, Levy WC, Wieselthaler GM, et al. Multicenter evaluation of an intrapericardial left ventricular assist system. J Am Coll Cardiol. 2011;57:1375–82.CrossRefPubMedGoogle Scholar
  51. 51.
    Arnaoutakis GJ, George TJ, Kilic A, Beaty CA, Weiss ES, Conte JV, et al. Risk factors for early death in patients bridged to transplant with continuous-flow left ventricular assist devices. Ann Thorac Surg. 2012;93:1549–54 (discussion 1555).CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    John R, Kamdar F, Eckman P, Colvin-Adams M, Boyle A, Shumway S, et al. Lessons learned from experience with over 100 consecutive HeartMate II left ventricular assist devices. Ann Thorac Surg. 2011;92:1593–9 (discussion 1599-1600).CrossRefPubMedGoogle Scholar
  53. 53.
    Nascimbene A, Hernandez R, George JK, Parker A, Bergeron AL, Pradhan S, et al. Association between cell-derived microparticles and adverse events in patients with nonpulsatile left ventricular assist devices. J Heart Lung Transpl. 2014;33:470–7.CrossRefGoogle Scholar
  54. 54.
    Urban M, Pirk J, Szarszoi O, Besik J, Netuka I. Post-heart transplantation outcome of HeartMate II-bridged recipients requiring unplanned concomitant temporary right ventricular mechanical support. Interact CardioVasc Thorac Surg. 2015;20:372–8.CrossRefPubMedGoogle Scholar
  55. 55.
    Whitson BA, Eckman P, Kamdar F, Lacey A, Shumway SJ, Liao KK, et al. Hemolysis, pump thrombus, and neurologic events in continuous-flow left ventricular assist device recipients. Ann Thorac Surg. 2014;97:2097–103.CrossRefPubMedGoogle Scholar
  56. 56.
    Saeed O, Jermyn R, Kargoli F, Madan S, Mannem S, Gunda S, et al. Blood pressure and adverse events during continuous flow left ventricular assist device support. Circ Heart Fail. 2015;8:551–6.CrossRefPubMedGoogle Scholar
  57. 57.
    Sandner SE, Riebandt J, Haberl T, Mahr S, Rajek A, Schima H, et al. Low-molecular-weight heparin for anti-coagulation after left ventricular assist device implantation. J Heart Lung Transpl. 2014;33:88–93.CrossRefGoogle Scholar
  58. 58.
    Tsiouris A, Paone G, Nemeh HW, Brewer RJ, Borgi J, Hodari A, et al. Lessons learned from 150 continuous-flow left ventricular assist devices: a single institutional 7 year experience. ASAIO J. 2015;61:266–73.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Sung M. Cho
    • 1
  • Nader Moazami
    • 2
  • Jennifer A. Frontera
    • 1
  1. 1.Department of NeurologyNew York UniversityBrooklynUSA
  2. 2.Heart and Vascular Institute, Cleveland ClinicClevelandUSA

Personalised recommendations